

Attorney Docket No.: 3802-090-27 CIP (105576-0033-102)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Karin Jooss et al.
Application No. : 10/807,449 Confirmation No.: 3354
Filed : March 24, 2004
For : CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS
Group Art Unit : 1644
Examiner : Ilia I. Ouspenski

Mail Stop Amendment
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

New York, New York 10036
September 4, 2009

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make the following patents and publications of record in the above-identified patent application:^{*}

U.S. Patent Document

<u>Patent/Application No.</u>	<u>Issue/Publication Date</u>	<u>Applicants</u>
2005/0053579	03/10/2005	Galipeau et al.

*A completed Form PTO/SB/08A/B listing these documents is attached hereto.

The above document was recently cited by the Examiner in the August 12, 2009 Office Action in co-pending U.S. application No. 10/404,662, filed April 2, 2003. This application claims priority under 35 U.S.C. § 120 from U.S. application No. 10/404,662. In accordance with 37 C.F.R. §§ 1.98(d) and 1.98(a)(2)(ii), applicants have not enclosed a copy of the document. However, applicants stand ready to provide a copy to the Examiner upon request.

Applicants respectfully request that the document be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicants also request that a copy of enclosed Form PTO/SB/08A/B, as considered and initialled by the Examiner, be returned with the next communication.

This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 C.F.R. § 1.97(c)). In accordance with 37 C.F.R. § 1.97, this Supplemental Information Disclosure Statement is accompanied by the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any fees required in connection with this Supplemental Information Disclosure Statement, or credit overpayment of the same, to Deposit Account No. 06-1075, Order No. 105576-0033-102.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Connie Wong (Reg. No. 62,901)
Attorneys for Applicants
ROPES & GRAY LLP
Customer No. 1473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (212) 596-9090